Literature DB >> 19888299

Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects.

Vinciane Wouters1, Nisha Limaye, Melanie Uebelhoer, Alexandre Irrthum, Laurence M Boon, John B Mulliken, Odile Enjolras, Eulalia Baselga, Jonathan Berg, Anne Dompmartin, Sten A Ivarsson, Loshan Kangesu, Yves Lacassie, Jill Murphy, Ahmad S Teebi, Anthony Penington, Paul Rieu, Miikka Vikkula.   

Abstract

Mutations in the angiopoietin receptor TIE2/TEK have been identified as the cause for autosomal dominantly inherited cutaneomucosal venous malformation (VMCM). Thus far, two specific germline substitutions (R849W and Y897S), located in the kinase domain of TIE2, have been reported in five families. The mutations result in a fourfold increase in ligand-independent phosphorylation of the receptor. Here, we report 12 new families with TEK mutations. Although the phenotype is primarily characterized by small multifocal cutaneous vascular malformations, many affected members also have mucosal lesions. In addition, cardiac malformations are observed in some families. Six of the identified mutations are new, with three located in the tyrosine kinase domain, two in the kinase insert domain, and another in the carboxy terminal tail. The remaining six are R849W substitutions. Overexpression of the new mutants resulted in ligand-independent hyperphosphorylation of the receptor, suggesting this is a general feature of VMCM-causative TIE2 mutations. Moreover, variation in the level of activation demonstrates, to the best of our knowledge for the first time, that widely differing levels of chronic TIE2 hyperphosphorylation are tolerated in the heterozygous state, and are compatible with normal endothelial cell function except in the context of highly localized areas of lesion pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19888299      PMCID: PMC2841708          DOI: 10.1038/ejhg.2009.193

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  20 in total

1.  Deletion of the carboxyl terminus of Tie2 enhances kinase activity, signaling, and function. Evidence for an autoinhibitory mechanism.

Authors:  Xi-Lin Niu; Kevin G Peters; Christopher D Kontos
Journal:  J Biol Chem       Date:  2002-06-24       Impact factor: 5.157

Review 2.  From germline towards somatic mutations in the pathophysiology of vascular anomalies.

Authors:  Nisha Limaye; Laurence M Boon; Miikka Vikkula
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

3.  Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2.

Authors:  M Vikkula; L M Boon; K L Carraway; J T Calvert; A J Diamonti; B Goumnerov; K A Pasyk; D A Marchuk; M L Warman; L C Cantley; J B Mulliken; B R Olsen
Journal:  Cell       Date:  1996-12-27       Impact factor: 41.582

4.  Structure of the Tie2 RTK domain: self-inhibition by the nucleotide binding loop, activation loop, and C-terminal tail.

Authors:  L M Shewchuk; A M Hassell; B Ellis; W D Holmes; R Davis; E L Horne; S H Kadwell; D D McKee; J T Moore
Journal:  Structure       Date:  2000-11-15       Impact factor: 5.006

5.  Deletion or substitution within the alpha platelet-derived growth factor receptor kinase insert domain: effects on functional coupling with intracellular signaling pathways.

Authors:  M A Heidaran; J H Pierce; D Lombardi; M Ruggiero; J S Gutkind; T Matsui; S A Aaronson
Journal:  Mol Cell Biol       Date:  1991-01       Impact factor: 4.272

6.  Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities.

Authors:  Laurence M Boon; John B Mulliken; Odile Enjolras; Miikka Vikkula
Journal:  Arch Dermatol       Date:  2004-08

7.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

8.  Assignment of a locus for dominantly inherited venous malformations to chromosome 9p.

Authors:  L M Boon; J B Mulliken; M Vikkula; H Watkins; J Seidman; B R Olsen; M L Warman
Journal:  Hum Mol Genet       Date:  1994-09       Impact factor: 6.150

9.  Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo.

Authors:  D J Dumont; G Gradwohl; G H Fong; M C Puri; M Gertsenstein; A Auerbach; M L Breitman
Journal:  Genes Dev       Date:  1994-08-15       Impact factor: 11.361

10.  The unique insert of cellular and viral fms protein tyrosine kinase domains is dispensable for enzymatic and transforming activities.

Authors:  G R Taylor; M Reedijk; V Rothwell; L Rohrschneider; T Pawson
Journal:  EMBO J       Date:  1989-07       Impact factor: 11.598

View more
  46 in total

1.  Microcephaly, intellectual impairment, bilateral vesicoureteral reflux, distichiasis, and glomuvenous malformations associated with a 16q24.3 contiguous gene deletion and a Glomulin mutation.

Authors:  Matthew G Butler; Susan L Dagenais; José L Garcia-Perez; Pascal Brouillard; Miikka Vikkula; Peter Strouse; Jeffrey W Innis; Thomas W Glover
Journal:  Am J Med Genet A       Date:  2012-03-09       Impact factor: 2.802

Review 2.  Pathogenesis of vascular anomalies.

Authors:  Laurence M Boon; Fanny Ballieux; Miikka Vikkula
Journal:  Clin Plast Surg       Date:  2011-01       Impact factor: 2.017

Review 3.  New and Emerging Targeted Therapies for Vascular Malformations.

Authors:  An Van Damme; Emmanuel Seront; Valérie Dekeuleneer; Laurence M Boon; Miikka Vikkula
Journal:  Am J Clin Dermatol       Date:  2020-10       Impact factor: 7.403

4.  Bleomycin induces endothelial mesenchymal transition through activation of mTOR pathway: a possible mechanism contributing to the sclerotherapy of venous malformations.

Authors:  Wei Zhang; Gang Chen; Jian-Gang Ren; Yi-Fang Zhao
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

5.  Common and specific effects of TIE2 mutations causing venous malformations.

Authors:  Marjut Nätynki; Jaakko Kangas; Ilkka Miinalainen; Raija Sormunen; Riikka Pietilä; Julie Soblet; Laurence M Boon; Miikka Vikkula; Nisha Limaye; Lauri Eklund
Journal:  Hum Mol Genet       Date:  2015-08-28       Impact factor: 6.150

6.  Angiopoietin receptor TEK mutations underlie primary congenital glaucoma with variable expressivity.

Authors:  Tomokazu Souma; Stuart W Tompson; Benjamin R Thomson; Owen M Siggs; Krishnakumar Kizhatil; Shinji Yamaguchi; Liang Feng; Vachiranee Limviphuvadh; Kristina N Whisenhunt; Sebastian Maurer-Stroh; Tammy L Yanovitch; Luba Kalaydjieva; Dimitar N Azmanov; Simone Finzi; Lucia Mauri; Shahrbanou Javadiyan; Emmanuelle Souzeau; Tiger Zhou; Alex W Hewitt; Bethany Kloss; Kathryn P Burdon; David A Mackey; Keri F Allen; Jonathan B Ruddle; Sing-Hui Lim; Steve Rozen; Khanh-Nhat Tran-Viet; Xiaorong Liu; Simon John; Janey L Wiggs; Francesca Pasutto; Jamie E Craig; Jing Jin; Susan E Quaggin; Terri L Young
Journal:  J Clin Invest       Date:  2016-06-06       Impact factor: 14.808

Review 7.  Vascular Anomalies Caused by Abnormal Signaling within Endothelial Cells: Targets for Novel Therapies.

Authors:  Ha-Long Nguyen; Laurence M Boon; Miikka Vikkula
Journal:  Semin Intervent Radiol       Date:  2017-09-11       Impact factor: 1.513

Review 8.  Classification of Vascular Anomalies: An Update.

Authors:  Jack E Steiner; Beth A Drolet
Journal:  Semin Intervent Radiol       Date:  2017-09-11       Impact factor: 1.513

Review 9.  The pathobiology of vascular malformations: insights from human and model organism genetics.

Authors:  Sarah E Wetzel-Strong; Matthew R Detter; Douglas A Marchuk
Journal:  J Pathol       Date:  2016-12-04       Impact factor: 7.996

Review 10.  Vascular anomalies: from genetics toward models for therapeutic trials.

Authors:  Melanie Uebelhoer; Laurence M Boon; Miikka Vikkula
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.